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Summary
Background The way in which a government chooses to ﬁ nance a health intervention can aﬀ ect the uptake of health 
interventions and consequently the extent of health gains. In addition to health gains, some policies such as public 
ﬁ nance can insure against catastrophic health expenditures. We aimed to evaluate the health and ﬁ nancial risk 
protection beneﬁ ts of selected interventions that could be publicly ﬁ nanced by the government of Ethiopia.
Methods We used extended cost-eﬀ ectiveness analysis to assess the health gains (deaths averted) and ﬁ nancial risk 
protection aﬀ orded (cases of poverty averted) by a bundle of nine (among many other) interventions that the 
Government of Ethiopia aims to make universally available. These nine interventions were measles vaccination, 
rotavirus vaccination, pneumococcal conjugate vaccination, diarrhoea treatment, malaria treatment, pneumonia 
treatment, caesarean section surgery, hypertension treatment, and tuberculosis treatment.
Findings Our analysis shows that, per dollar spent by the Ethiopian Government, the interventions that avert the most 
deaths are measles vaccination (367 deaths averted per $100 000 spent), pneumococcal conjugate vaccination (170 deaths 
averted per $100 000 spent), and caesarean section surgery (141 deaths averted per $100 000 spent). The interventions 
that avert the most cases of poverty are caesarean section surgery (98 cases averted per $100 000 spent), tuberculosis 
treatment (96 cases averted per $100 000 spent), and hypertension treatment (84 cases averted per $100 000 spent).
Interpretation Our approach incorporates ﬁ nancial risk protection into the economic evaluation of health interventions 
and therefore provides information about the eﬃ  ciency of attainment of both major objectives of a health system: 
improved health and ﬁ nancial risk protection. One intervention might rank higher on one or both metrics than 
another, which shows how intervention choice—the selection of a pathway to universal health coverage—might 
involve weighing up of sometimes competing objectives. This understanding can help policy makers to select 
interventions to target speciﬁ c policy goals (ie, improved health or ﬁ nancial risk protection). It is especially relevant 
for the design and sequencing of universal health coverage to meet the needs of poor populations.
Funding Bill & Melinda Gates Foundation.
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Introduction
Protection from ﬁ nancial risks associated with health-
care expenses is emerging as a crucial component of 
national health strategies in many low-income and 
middle-income countries. WHO’s World Health Reports 
of 1999 and 2000 and the World Bank’s Flagship course 
in health ﬁ nance included provision of ﬁ nancial risk 
protection as one criterion of good performance for 
health systems.1–3 The reduction of these ﬁ nancial risks is 
one objective of health policy devices such as universal 
public ﬁ nance—full public ﬁ nance irrespective of 
whether services are provided privately or publicly.
Out-of-pocket medical payments can lead to 
impoverishment in many countries, with households 
choosing from many coping strategies to manage health-
related expenses.4,5 These strategies include borrowing 
money from peers or relatives, or selling assets to pay for 
their health care. A quarter of individuals in low-income 
and middle-income countries use these ﬁ nancing 
mechanisms.6 Without other options, such as private 
health insurance, household medical expenditures can 
often be catastrophic,7 which is deﬁ ned as expenditures 
exceeding a particular fraction of total household 
expenditures.
Universal public ﬁ nance implies that the government 
ﬁ nances an intervention irrespective of who is delivering 
or receiving it. Funds for universal public ﬁ nance can be 
raised from general taxation, social insurance, external 
(donor) funding, or a combination of these sources. 
Recently, the 2010 World Health Report8 advocated for a 
path to universal coverage, and identiﬁ ed reliance on 
direct payments, such as user fees at the point of care, as 
the greatest obstacle to progress on this path. By reducing 
some of the ﬁ nancial barriers to access, universal public 
ﬁ nance is a key policy device for promoting universal 
health coverage, and it was stressed by The Lancet’s 
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Commission on Investing in Health as a key instrument 
for progressive universalist pathways to achieve universal 
health coverage.9 Although in many high-income 
countries, universal public ﬁ nance covers a wide range of 
necessary health services, in low-income and middle-
income countries, universal public ﬁ nance typically 
targets a few selected interventions in the form of an 
essential health package. Consequently, many health 
services, including preventive and curative care, require 
payment at the point of care. Although essential care 
packages have elements in common, such as basic 
maternal and child health services, no clear consensus has 
been reached regarding the interventions to be included 
in a beneﬁ ts package ﬁ nanced by universal public ﬁ nance.
By ﬁ nancing interventions fully, universal public 
ﬁ nance increases coverage in poor population groups.8,10 
Tradition ally, economic assessments of health 
interventions (cost-eﬀ ectiveness analysis) have focused 
on health improvement and have estimated an 
intervention cost per health gain, in dollars per death 
averted or dollars per disability-adjusted life-year averted.11 
Extended cost-eﬀ ectiveness analysis (ECEA)12–14 
supplements traditional economic evaluation with 
ﬁ nancial risk protection evaluation (ie, assessment of the 
number of cases of poverty averted). This analysis enables 
the design of beneﬁ ts packages that quantify ﬁ nancial 
risk protection and health that can be purchased for a 
given expenditure on speciﬁ c interventions. In this 
respect, ECEA can inform discussion of some of the 
policy questions raised by the World Health Report 201315 
about how to select and sequence the health services to be 
provided, to improve service coverage, and to increase 
ﬁ nancial risk protection for households.
In this Article, we apply ECEA to measure health and 
ﬁ nancial risk protection beneﬁ ts for nine interventions 
that could be publicly ﬁ nanced by the Government of 
Ethiopia. Ethiopia has Africa’s second largest population 
at about 92 million people, 82% of whom live in rural 
areas.16 It is a low-income country with a gross domestic 
product (GDP) per person of about US$360, a growth rate 
of 7–8% per year, about 30% of its population living below 
the national poverty line, and a large share (roughly a 
third) of health expenditures ﬁ nanced by out-of-pocket 
payments.17 Recently, Ethiopia’s Ministry of Health has 
outlined an ambitious Health Sector Development 
Program for 2010–15,18 which aims to scale up coverage of 
key interventions, many of which we explore in this 
analysis. Ethiopia expects to achieve its targets in large 
part due to the Health Extension Program—a community-
based health services delivery programme that has helped 
to expand access to primary health care.19,20
Methods
Interventions
We selected interventions that encompassed a range of 
health conditions, diﬀ erent age groups (children vs adults), 
various incidences, and health expenditures (table 1). 
These inter ventions were among the national priorities of 
Ethiopia’s Ministry of Health.18 The interventions included 
were: measles vaccination; rotavirus vaccination; pneumo-
coccal conjugate vaccination; diarrhoea treatment; malaria 
treatment; pneumonia treatment; caesarean section 
surgery; tuberculosis directly observed treatment short 
course; and treatment of hypertension. These interventions 
are a subset of health priorities taken from the list of 
interventions that the government aims to make 
universally accessible.18 These speciﬁ c ones were selected 
because they had the most data available and encompassed 
a range of conditions, ages, incidences, expenditures, and 
resources needed, thus showing the broad trade-oﬀ s 
between health and ﬁ nancial risk protection beneﬁ ts. Our 
analysis is therefore illustrative, rather than comprehensive 
or prescriptive.
Assumptions
We analysed the eﬀ ects of universal public ﬁ nancing—
whereby individuals would not need to spend any money 
out of pocket to cover the direct medical costs—for each of 
the nine interventions. Full public ﬁ nance is applied to the 
present coverage of the intervention plus a speciﬁ ed 
(10 percentage point) increment in intervention coverage 
(table 1). 10 percentage points are thought to represent an 
achievable increment amount within a short period (ie, 
1 year), in view of existing health system capacity. We 
acknowledge that the amount of information diﬀ usion, 
implicit and explicit demand creation, and availability of 
services could all increase after the implementation of 
universal public ﬁ nance. Generally, the expected increment 
would depend on various issues, including present 
coverage, with, for example, low and high coverage seeing 
lower increases (low coverage because of low access; high 
coverage because of diﬃ  culties to improve further) than 
average coverage. We therefore explore the sensitivity of 
our ﬁ ndings to the selection of diﬀ erent incremental 
scenarios (5 and 20 percentage point increases).
For each intervention, we estimated both the total 
number of deaths averted and the total ﬁ nancial risk 
protection aﬀ orded owing to a reduction in out-of-pocket 
expenditures associated with treatment, per year. The 
amount of death and medical impoverishment prevented 
by public ﬁ nancing of each intervention depends on 
intervention coverage, intervention eﬀ ectiveness, and 
household expenditures for treatment of related diseases. 
Despite some services being provided free of charge by 
the government (ie, essential services related to family 
health, control of communicable diseases, hygiene and 
environmental sanitation, treatment for major chronic 
illnesses, and health education and communication),27 
34% of health expenditure is ﬁ nanced privately in 
Ethiopia.17 This expenditure consists of direct outlays by 
households (including gratuities and in-kind payments) 
for health services. For consistency, we assume that an 
individual’s out-of-pocket burden for treating a disease or 
condition before universal public ﬁ nance is 34% of the 
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Description Target population Coverage 
before UPF (%)
Coverage after 
UPF (%)
Source(s)
Rotavirus vaccine Routine immunisation through EPI two-dose vaccine Children <1 year of age 0% 10% Ethiopia Central Statistical Agency 
and ICF International21
Pneumococcal conjugate 
vaccine
Routine immunisation through EPI three-dose vaccine Children <1 year of age 0% 10% Ethiopia Central Statistical Agency 
and ICF International21
Measles vaccine Routine immunisation through EPI one-dose vaccine Children <1 year of age 56% 66% Ethiopia Central Statistical Agency 
and ICF International21
Diarrhoea treatment Provision of oral rehydration solution for mild diarrhoea 
(outpatient visit) and of intravenous ﬂ uids for severe diarrhoea 
(inpatient visit)
Children <5 years of age 32% 42% Ethiopia Central Statistical Agency 
and ICF International21
Pneumonia treatment Provision of oral antibiotics (eg, amoxicillin) for mild 
pneumonia (outpatient visit), and of injectable antibiotics 
(eg, penicillin/ampicillin) and oxygen for severe pneumonia 
(inpatient visit)
Children <5 years of age 27% 37% Ethiopia Central Statistical Agency 
and ICF International21
Malaria treatment Provision of artemisinin combination therapy for mild malaria 
(outpatient visit) and of intravenous treatment (eg, quinine) for 
severe malaria (inpatient visit)
Children <5 years of age 24% 34% Ethiopia Central Statistical Agency 
and ICF International21
Caesarean section surgery Surgical delivery for pregnant women in need of caesarean section Pregnant women in need 
of caesarean section
Urban 83%; 
rural 15%
Urban 83%; 
rural 25%
Ethiopia Central Statistical Agency 
and ICF International21
Tuberculosis treatment Provision of directly observed treatment, short course Adults (15–49 years of age) 50% 60% WHO22
Hypertension treatment Provision of hydrochlorothiazide, amlodipine, and enalapril for 
high blood pressure
Adults (40–59 years of age) 
at high risk*
34%† 44%† Zenebe,23 Bovet et al,24 Elzubier,25 
and WHO26
UPF=universal public ﬁ nance. EPI=Expanded Programme on Immunization. *34% of adults are at high risk in ubran areas and 5% of adults are at high risk in rural areas.†60% compliance. Universal public 
ﬁ nance—ie, full public ﬁ nance—is applied to the current coverage of the intervention plus a speciﬁ ed (10%) increment in the intervention coverage. 10% is thought to represent an achievable increment amount 
within a short period (ie, 1 year), in view of existing health system capacity.
 Table 1: Interventions ﬁ nanced by hypothetical provision of universal public ﬁ nance in Ethiopia
Disease burden Case-fatality 
rate (%)
Health-care use (%) Household out-of-
pocket payments 
before UPF (2011 US$)
Unit costs borne by 
government after 
UPF (2011 US$)
Eﬀ ectiveness 
(%)
Rotavirus vaccine21,28,29–35 3·9 under-5 deaths per 1000 livebirths 0·34% Inpatient: 1·5%;
outpatient: 31%
Inpatient: 17;
outpatient: 3
3·0* 49%
Pneumococcal conjugate 
vaccine21,28,29,32–34,36–39
8·0 under-5 deaths per 1000 livebirths† Pneumonia 11%;
meningitis 73%;
non-pneumonia 
non-meningitis 
disease 58%
Inpatient: pneumonia 9%, 
meningitis 75%, 
non-pneumonia 
non-meningitis disease 75%;
outpatient: pneumonia 
27%, meningitis 75%, 
non-pneumonia 
non-meningitis disease 75%
Inpatient: 28;
outpatient: 15;
meningitis: 62 
(inpatient and 
outpatient)
4·6* 80%
Measles vaccine28,29,32–34,40–42 4·0 under-5 deaths per 1000 livebirths 3·5% Inpatient 2·5%;
outpatient: 50%
Inpatient: 5;
outpatient: 0·5
1·0 85%
Diarrhoea 
treatment21,28,29,33,34,43–45
14·7 under-5 deaths per 1000 livebirths 0·15% Inpatient: 0·5%;
outpatient: 31%
Inpatient: 17;
outpatient: 3
Inpatient: 49;
outpatient: 7
93%
Pneumonia 
treatment21,28,29,33,34,37,46
22·1 under-5 deaths per 1000 livebirths 2·6% Inpatient: 9%;
outpatient: 27%
Inpatient: 28;
outpatient: 15
Inpatient: 84;
outpatient: 45
70%
Malaria 
treatment21,28,29,33,34,47–49
1·7 under-5 deaths per 1000 livebirths 4·2% Inpatient: 13%;
outpatient: 24%
Inpatient: 14;
outpatient: 4
Inpatient: 42;
outpatient: 12
91%
Caesarean section 
surgery21,28,50–55
7·5 women in need per 1000 livebirths 30% Urban: 83%;
rural: 15%
Urban: 67;
rural: 31
Urban: 197;
rural: 92
99%
Tuberculosis treatment22,56,57 100 000 annual cases‡ 32% 50% 90 263 83%
Hypertension treatment58–60 56 annual cases per 100 000 (stroke)§; 
35 annual cases per 100 000 (ischaemic heart 
disease)§
Stroke: 45%;
ischaemic heart 
disease: 66%
75% upon stroke/ischaemic 
heart disease event
Stroke: 65;
ischaemic heart disease: 
84
9 Stroke: 39;
ischaemic heart 
disease: 30
UPF=universal public ﬁ nance.*Cost per vaccine dose is assumed to be US$1. †Pneumococcal deaths include pneumonia (90%), meningitis (7%), and non-pneumonia non-meningitis disease (3%). ‡By virtue of 
recommending smear microscopy, directly observed treatment short course focuses on the detection of smear-positive tuberculosis cases. Thus, our analysis focuses on smear-positive tuberculosis cases only. 
§54% of stroke incidence in people at high risk; 47% of ischaemic heart disease incidence in people at high risk.
Table 2: Summary of the parameters used for modelling of universal public ﬁ nance for nine interventions in Ethiopia
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total treatment cost (direct medical cost). In other words, 
for the purpose of this modelling exercise, before universal 
public ﬁ nance, individuals pay 34% of health-care costs 
and the government pays 66% of the costs. After universal 
public ﬁ nance, individuals pay no health-care costs and 
the government pays all (100%) of them. In this modelling 
exercise, no other out-of-pocket direct medical costs were 
included (eg, costs of visits to many providers because of 
poor health-seeking behaviour). We use secondary data 
and published studies to estimate the costs of the nine 
speciﬁ c interventions analysed here. All costs are 
expressed in 2011 US$.
The number of deaths averted by each intervention is 
estimated on the basis of incidence and mortality data (ie, 
the burden attributed to the disease before universal 
public ﬁ nance), intervention eﬀ ectiveness and coverage, 
and the case-fatality rate (table 2). Financial risk protection 
is measured by estimation of the total number of cases of 
poverty averted for each intervention, depending on 
individual income (a proxy for which can be extracted 
from the income distribution of Ethiopia derived from its 
GDP per head [$360 in current US$] and its Gini index 
[34]), the national poverty line, the population targeted, 
disease incidence, health-care use, and out-of-pocket 
payments. The number of poverty cases averted is 
measured as the number of individuals who no longer fall 
below the national poverty line.61 Speciﬁ cally, in the 
population targeted, we estimate the individuals’ expected 
income before and after universal public ﬁ nance 
(depending on incidence, treatment costs, intervention 
coverage, and eﬀ ectiveness), and subsequently count how 
many people have their expected income move up across 
the poverty line after the implementation of universal 
public ﬁ nance.
Statistical analysis
The appendix provides full details of the mathematical 
derivations used for the analysis. Table 2 lists all the 
parameters used for the selected interventions. We used 
R statistical software version 3.1.0 for all analyses.
Role of the funding source
The funder of the study had no role in study design, or 
data collection, analysis, or interpretation. SV and all 
coauthors had full access to all the data in the study. SV 
and DTJ had ﬁ nal responsibility for the decision to submit 
for publication.
Results
The total intervention costs, the extent of health gains, 
and ﬁ nancial risk protection provided vary substantially 
across the nine interventions ﬁ nanced through universal 
public ﬁ nance (table 3). The total number of deaths 
averted by the interventions per US$100 000 spent ranges 
from seven (for diarrhoea treatment) to 367 (for measles 
vaccination; ﬁ gure). The total number of poverty cases 
averted varies substantially, from six (for measles vaccine) 
to 98 (for caesarean section) per $100 000 spent.
Measles and pneumococcal conjugate vaccinations are 
the two interventions that prevent the highest number of 
deaths per $100 000 spent, since the measles vaccine 
averts 367 deaths and pneumococcal conjugate vaccine 
170 deaths. The measles vaccine is very eﬀ ective (85% 
eﬃ  cacy), is quite inexpensive (US$1·0 per child), and the 
disease is highly fatal (3·5% case-fatality rate). By contrast, 
diarrhoea treatment prevents the smallest number of 
deaths per $100 000 spent (roughly seven), since the 
intervention is not so cheap (US$6 for outpatient visits 
and $34 for inpatient visits) and diarrhoea is rarely fatal 
(0·15% case-fatality rate). Similarly, treatment of 
hypertension averts only 11 deaths per $100 000 spent, 
partly because of the low estimated incidence of stroke 
and ischaemic heart disease (<100 per 100 000 population) 
and the low eﬀ ectiveness of this treatment (39% eﬀ ective 
Government 
intervention costs 
(2011 US$)
Household 
expenditures 
averted (2011 US$)
Deaths 
averted
Cases of 
poverty 
averted
Rotavirus vaccine 800 000 180 000 510 (4) 270 (7)
Pneumococcal conjugate vaccine 1 200 000 110 000 1700 (2) 170 (8)
Measles vaccine 260 000 9000 890 (1) 14 (9)
Diarrhoea treatment 50 000 000 26 000 000 3600 (9) 40 000 (4)
Pneumonia treatment 31 000 000 15 000 000 4100 (7) 23 000 (5)
Malaria treatment 670 000 300 000 410 (5) 460 (6)
Caesarean section surgery 420 000 270 000 590 (3) 410 (1)
Tuberculosis treatment 6 900 000 4 400 000 2600 (6) 6700 (2)
Hypertension treatment 1 300 000 730 000 140 (8) 1100 (3)
The numbers in parentheses are the ranking of each intervention in deaths averted per dollar spent and poverty cases 
averted per dollar spent.
Table 3: Total government intervention costs, household expenditures averted, deaths averted, and 
poverty cases averted, for each of the nine interventions provided by universal public ﬁ nance in Ethiopia
Figure: Financial risk protection aﬀ orded (poverty cases averted) versus health 
gains (deaths averted), per US$100 000 spent (in 2011 US$), for each of the 
nine interventions provided through universal public ﬁ nance in Ethiopia
Dashed line represents a trend line.
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at preventing stroke and 30% eﬀ ective at preventing 
ischaemic heart disease).
Conversely, caesarean section averts the highest number 
of poverty cases (98 cases averted) because the associated 
out-of-pocket costs are large (US$30–70) and the number 
of pregnant women in need of caesarean section is 
substantial (around eight per 1000 pregnant women). 
Similarly, tuberculosis treatment and hypertension 
treatment lead to the second and third highest number of 
poverty cases averted (96 and 84 poverty cases averted, 
respectively), since they also create substantial out-of-
pocket payments (US$65–90). Measles vaccination averts 
the smallest number of poverty cases (six), since the out-of-
pocket payments by the beneﬁ ciary are small ($5 for 
inpatient visits and $0·50 for outpatient visits). Overall, 
adult treatment interventions (tuberculosis treatment, 
caesarean section, and hypertension treatment) provide 
the greatest ﬁ nancial risk protection. The vaccine 
interventions (measles, rotavirus, and pneumococcal 
conjugate vaccines) produce less ﬁ nancial risk protection 
(per dollar spent) than the childhood treatment 
interventions (treatment for malaria, diarrhoea, and 
pneumonia). In particular, one potential approach for 
subsequent interpretation could be to infer a trend line 
(ﬁ gure) highlighting substitution between health and 
ﬁ nancial risk protection beneﬁ ts: for example, a linear 
approximation (R²=0·61) points to a reduction of about 
two poverty cases averted per additional ten deaths averted. 
Trade-oﬀ s inferred from such a trend line or from a 
frontier (ie, the line joining the caesarean section and 
measles immunisation points [not shown]) can prove 
highly sensitive to the interventions included. For example, 
if the measles vaccine were excluded, the R² would be 
reduced to 0·29.
Finally, we assessed the sensitivity of our ﬁ ndings with 
respect to a change in coverage increment (5% or 20%; 
table 4). For the vaccines, when coverage increment 
changes, health and ﬁ nancial risk protection beneﬁ ts per 
dollar spent are maintained. For all the other 
interventions, when coverage increment decreases (to 
5%), per dollar spent, ﬁ nancial risk protection beneﬁ ts 
increase and health beneﬁ ts decrease; conversely, when 
coverage increases (to 20%), per dollar spent, ﬁ nancial 
risk protection beneﬁ ts decrease and health beneﬁ ts 
increase.
Discussion
We present results for an ECEA of universal public 
ﬁ nancing of nine health interventions in Ethiopia. In 
particular, our approach assesses the consequences of 
universal public ﬁ nance in protecting families against 
ﬁ nancial impoverishment, in addition to the dimension 
of health gains. This type of analysis is not possible with 
a traditional cost-eﬀ ectiveness analysis, and emphasises 
potential trade-oﬀ s for policy makers as they choose 
between alternative pathways to universal health 
coverage (panel).
The introduction of universal public ﬁ nance for key 
interventions could bring major ﬁ nancial risk protection 
beneﬁ ts in addition to substantial health gains. Our 
ﬁ ndings align well with several expectations. First, if we 
assess health gains per dollar spent, the results fall 
within the range of previously reported cost-eﬀ ectiveness 
analysis estimates.11 Second, the conditions with large 
out-of-pocket payments are associated with high ﬁ nancial 
risk protection, and low-cost interventions (eg, treatment 
for hypertension) can lead to large poverty alleviation 
beneﬁ ts. In addition to cost-eﬀ ective interventions for 
which eﬃ  cient purchase of health gains is realised (eg, 
the measles vaccine), there are so-called ﬁ nancial risk 
protection—cost-eﬀ ective interventions for which 
eﬃ  cient purchase of ﬁ nancial risk protection beneﬁ ts is 
realised (eg, hypertension treatment).
Although ECEA is neutral with respect to what ought 
to be prioritised and included in a beneﬁ ts package, the 
method allows policy makers to take both health and 
ﬁ nancial risk protection into account when making 
decisions. Consequently, scarce health-care resources 
could be more eﬀ ectively targeted in accordance with 
speciﬁ c policy objectives. For example, although 
potentially discarded on the grounds of health beneﬁ ts, 
hypertension treatment might be included in a beneﬁ ts 
package based on ﬁ nancial risk protection beneﬁ ts. 
Similarly, based on our calculations, public ﬁ nancing of a 
Government 
intervention costs 
(2011 US$)
Household 
expenditures 
averted (2011 US$)
Deaths 
averted
Cases of 
poverty 
averted
5% increase in coverage
Rotavirus vaccine 400 000 90 000 250 (3) 140 (7)
Pneumococcal conjugate vaccine 600 000 55 000 840 (2) 80 (8)
Measles vaccine 130 000 5000 450 (1) 10 (9)
Diarrhoea treatment 38 000 000 26 000 000 1800 (9) 40 000 (4)
Pneumonia treatment 23 000 000 15 000 000 2000 (7) 23 000 (5)
Malaria treatment 480 000 300 000 210 (5) 460 (6)
Caesarean section surgery 340 000 266 000 290 (4) 410 (1)
Tuberculosis treatment 5 600 000 4 400 000 1300 (6) 6700 (2)
Hypertension treatment 1 000 000 730 000 70 (8) 1100 (3)
20% increase in coverage
Rotavirus vaccine 1 600 000 350 000 1000 (4) 540 (4)
Pneumococcal conjugate vaccine 2 400 000 220 000 3300 (3) 340 (8)
Measles vaccine 520 000 19 000 1800 (1) 30 (9)
Diarrhoea treatment 75 000 000 26 000 000 7200 (9) 40 000 (5)
Pneumonia treatment 47 000 000 15 000 000 8100 (7) 23 000 (6)
Malaria treatment 1 030 000 300 000 820 (5) 460 (7)
Caesarean section surgery 570 000 270 000 1200 (2) 410 (1)
Tuberculosis treatment 9 500 000 4 400 000 5200 (6) 6700 (2)
Hypertension treatment 2 000 000 730 000 280 (8) 1200 (3)
The numbers in parentheses are the ranking of each intervention in deaths averted per dollar spent and poverty cases 
averted per dollar spent. 
Table 4: Total government intervention costs, household expenditures averted, deaths averted, and 
poverty cases averted, for each of the nine interventions provided by universal public ﬁ nance in 
Ethiopia, after a 5% or a 20% increase in coverage
Articles
e293 www.thelancet.com/lancetgh   Vol 3   May 2015
10% increase in tuberculosis treatment and a 10% 
increase in malaria treatment would provide similar 
health beneﬁ ts per dollar spent. However, tuberculosis 
treatment provides substantially more ﬁ nancial risk 
protection than malaria treatment and therefore is likely 
to be the better investment until resources are available 
for both. This analysis also provides policy makers with 
information about how they might sequence the 
development of health-care packages as the health and 
ﬁ nancial needs of populations evolve and resource 
envelopes change. Finally, health policies can be 
compared with policies from other sectors aimed at 
poverty reduction (eg, education, transportation, and 
development).
Our analysis has some limitations. Most importantly, 
with respect to our Ethiopian case study, we studied a 
small number of Ethiopia’s health priorities.18 This 
selection was largely because of scarce data availability, 
with nonetheless the intent to include a range of 
conditions, ages, incidences, expenditures, and resources 
needed across interventions, so as to illustrate broad 
health–ﬁ nancial risk protection trade-oﬀ s. The analysis is 
therefore illustrative: it is neither comprehensive nor 
prescriptive. Speciﬁ cally, through its Health Extension 
Program,19,20,62 Ethiopia has introduced community-based 
primary health care. The programme proposes 17 
packages of basic services in four subdomains: disease 
prevention and control; family health; hygiene and 
environmental sanitation; and health education and 
communication. Every community builds a health post; 
two health extension workers from the community are 
trained to provide households with disease prevention 
advice, accessible services at health posts, and referrals to 
health centres.19 Therefore, a detailed case study should 
represent this comprehensive design; our analysis 
presents a selective primary health-care view, largely 
because of low data availability and our aim to be 
illustrative. Thus, several key interventions from these 
subdomains, including prevention of mother-to-child 
transmission of HIV, family planning and reproductive 
health, and treatment of neglected tropical diseases, were 
not included. 
Similarly, integration of services including reduced costs 
through economies of scope and synergistic eﬀ ects rather 
than single interventions was not considered. Therefore, 
the selection of an optimum bundle of existing and new 
packages for the Health Extension Program, with 
comprehensive assessment of opportunity costs, health, 
and ﬁ nancial risk protection beneﬁ ts remains to be done 
in future work. Importantly, in doing so, one should learn 
from other low-income and middle-income countries that 
have introduced publicly funded services towards universal 
health coverage.63 For example, Rwanda’s experience 
suggests that mutual health insurance increased health-
care use and ﬁ nancial risk protection.64 Through its Health 
Transformation Program, Turkey substantially enhanced 
equity with an improved level and distribution of health, 
more fairness in ﬁ nancing, and insurance coverage rising 
from 2 to 10 million people within 10 years.65 In another 
example, Thailand’s health reforms increased insurance 
coverage and signiﬁ cantly reduced child mortality in the 
poorest groups.66
Second, ECEA is only one method for priority setting. In 
addition to cost-eﬀ ectiveness analysis or ECEA, decision-
making should also include other ethical, social, political, 
and economic considerations, such as beneﬁ t to cost 
ratios;9 the strengths and weaknesses of the host health 
systems; and use several criteria including those related to 
disease (eg, severity), targeting only speciﬁ c individuals 
(eg, high-risk individuals) rather than a wider group of 
individuals, and other non-health consequences (eg, 
education).67,68 By introducing ECEA, we intend to address 
some of these well understood limits of cost-eﬀ ectiveness 
analysis69 such as ﬁ nancial risk protection (one important 
dimension of universal health coverage), but much 
remains to be done in addressing how to improve these 
extensions and to deal with the concerns about cost-
eﬀ ectiveness analysis that ECEA does not yet address. 
Unlike most other ECEAs,12–14 in this report, we did not 
disaggregate results by income quintile and did not directly 
address the issue of equity. If a government were to 
prioritise interventions, there would be equity implications 
and the need for disaggregated analyses. We focused on 
ﬁ nancial risk protection because of scarce data and to be 
parsimonious in adding dimensions to health beneﬁ ts.
Third, as is the case with many published cost-
eﬀ ectiveness analyses, our disease models are static 
Panel: Research in context
Systematic review
The 2010 World Health Report8 advocated for a path to universal health coverage, and 
The Lancet’s Commission on Investing in Health9 outlined alternative potential pathways to 
achieve this goal. The World Health Reports of 1999 and 20001,2 and the World Bank’s 
Flagship course in health ﬁ nance3 included provision of ﬁ nancial risk protection as one 
criterion of good performance for health systems. Traditionally, economic analyses of 
health interventions have focused on health improvement per dollar spent. Extended cost-
eﬀ ectiveness analysis (ECEA)12–14 supplements traditional economic evaluation with 
estimation of ﬁ nancial risk protection provided by health ﬁ nancing policies. Universal 
public ﬁ nance is unique in that the government ﬁ nances an intervention irrespective of 
who is delivering or receiving it. By contrast, although much has been written about the 
impoverishing eﬀ ect of health expenditures, little attention has been paid to how public 
resources can be used eﬃ  ciently to protect against this risk. In this Article, we apply ECEA to 
measure both health and ﬁ nancial risk protection beneﬁ ts for a bundle of nine (among 
many other) interventions to be universally publicly ﬁ nanced by the Government of 
Ethiopia.
Interpretation
Our approach incorporates ﬁ nancial risk protection into the economic evaluation of 
health policy. This step allows policy makers to establish how much ﬁ nancial risk 
protection is being purchased with a given beneﬁ ts package, in addition to the 
assessment of health that is being bought with incremental increases in public spending. 
The approach can inform the design of essential health packages on the pathway to 
universal health coverage.
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rather than dynamic. Compared with static models, 
dynamic models can more accurately capture synergies 
but also have a bigger reliance on additional data and 
assumptions about disease behaviour. The inclusion of 
the number of secondary cases prevented would lead to 
increased numbers of deaths and poverty cases averted 
(for example, an increase to 41 deaths averted and 
97 poverty cases averted per $100 000 spent for 
tuberculosis treatment). Additionally, the longer term 
beneﬁ ts of vaccination in those older than 5 years of age 
were neglected because the burden of disease is largely 
concentrated in children younger than 5 years of age.
Fourth, a more comprehensive accounting of household 
medical payments could be done, including payments 
caused by poor health-seeking behaviour and visits from 
many health-care providers. In particular, direct non-
medical costs (eg, transportation and housing costs) and 
indirect costs caused by the disease or condition, 
including loss of earnings and eﬀ ect on labour 
productivity, can be substantial. Fifth, scarce data about 
the existing mix of public and private provision and 
purchase of health care aﬀ ected our choice of 
interventions. Sixth, we did not do a full uncertainty 
analysis but rather included a sensitivity analysis, since 
the purpose of this report is to expose with simplicity a 
methodological framework for policy makers, and not to 
provide them with deﬁ nitive estimates. Finally, we chose 
to represent ﬁ nancial risk protection in terms of poverty 
cases averted. Alternatives include a money-metric value 
of insurance wherein a utility-based framework is used 
and in which individuals seek to avoid uncertainty,12 and 
avoid cases of forced borrowing or sales.6 We chose the 
metric of poverty cases averted because of both data 
availability and simplicity. However, the use of this metric 
has associated issues— namely, the choice of a poverty 
threshold and the fact that individuals living below the 
poverty line might not always be accounted for.7 Similarly, 
we relied heavily on secondary data and published studies 
to estimate eﬀ ect and costs. Moreover, the health metric 
of deaths averted was retained for simplicity and ease of 
communication, which could introduce bias towards 
high-mortality diseases, and could be replaced by a 
constructed metric capturing both morbidity and 
mortality such as the disability-adjusted life-year.
Future studies will expand on this analysis by 
incorporating other essential features that promote 
realism of the scenario. For example, ﬁ nancial barriers 
are not the only barriers that prevent individuals from 
seeking care: absence of information, low availability of 
services, and long distances to health-care facilities are 
also important. In countries with a low density of health 
workers and weak health infrastructure, such as Ethiopia, 
health services might not be available even after some of 
the ﬁ nancial barriers are removed. In particular, 
expansion of health services to rural areas might need 
additional investments, such as strengthening of health 
facilities through training and deployment of skilled 
health workers, provision of essential equipment, and 
infrastructural improvement for service delivery. 
Acceptability issues related to culture or quality also 
exist. Universal health coverage does not necessarily 
ensure quality, but innovations, such as accreditation to 
participate in universal health coverage schemes70 
instituting basic quality expectations or pay for 
performance schemes, can improve quality. In turn, these 
barriers will limit expansion in the amount of coverage 
initially achievable by universal public ﬁ nance. To address 
this situation, we chose a speciﬁ ed coverage increment of 
10% for all interventions. However, the expected 
increment would depend on various issues, including 
present coverage, which is why we included a sensitivity 
analysis. Moreover, marginal costs of health-care 
provision might increase substantially with coverage 
increase, and these marginal costs can vary depending on 
the population subgroups targeted (eg, diﬀ erent 
education or socioeconomic groups). Similarly, signiﬁ cant 
diﬀ erences exist in disease incidence or mortality, and 
health-care use, which vary by population subgroups. For 
example, poorer children are more likely to die from 
rotavirus than are those from wealthier families, and 
richer children are more likely than poor children to be 
taken to health facilities when they are ill.13 Finally, ECEA 
can be applied to the evaluation of other policy devices 
besides universal public ﬁ nance, including prepayment 
mechanisms (eg, who should ﬁ nancially contribute and 
in which way), conditional cash transfers, or ﬁ nancial 
incentives.
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